Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Kunath

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
BMJ Open|December 8, 2011
Do urology journals enforce trial registration? A cross-sectional study of published trialsFrank Kunath, Henrik R Grobe, Bastian Keck, et al.
BMC Neuroscience|March 5, 2009
Perisylvian white matter connectivity in the human right hemisphereAlireza Gharabaghi, Frank Kunath, Michael Erb, et al.
The Cochrane Database of Systematic Reviews|May 10, 2017
Partial nephrectomy versus radical nephrectomy for clinical localised renal massesFrank Kunath, Stefanie Schmidt, Laura-Maria Krabbe, et al.
The Cochrane Database of Systematic Reviews|June 14, 2019
Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancerFrank Kunath, Katrin Jensen, Mariona Pinart, et al.
The Cochrane Database of Systematic Reviews|July 1, 2014
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerFrank Kunath, Henrik R Grobe, Gerta Rücker, et al.
BJU International|December 20, 2014
Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic reviewFrank Kunath, Henrik R Grobe, Gerta Rücker, et al.
Annals of Surgical Oncology|October 31, 2012
Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladderBastian Keck, Sven Wach, Frank Kunath, et al.
The Cochrane Database of Systematic Reviews|August 5, 2021
Degarelix for treating advanced hormone-sensitive prostate cancerFriedemann Zengerling, Joachim J Jakob, Stefanie Schmidt, et al.
The Cochrane Database of Systematic Reviews|December 14, 2020
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancerNiranjan J Sathianathen, Makinna C Oestreich, Sarah Jane Brown, et al.
Diagnostics (Basel, Switzerland)|November 14, 2023
Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service PointCarla E Schulmeyer, Matthias W Beckmann, Peter A Fasching, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
BMJ Open|December 8, 2011
Do urology journals enforce trial registration? A cross-sectional study of published trialsFrank Kunath, Henrik R Grobe, Bastian Keck, et al.
BMC Neuroscience|March 5, 2009
Perisylvian white matter connectivity in the human right hemisphereAlireza Gharabaghi, Frank Kunath, Michael Erb, et al.
The Cochrane Database of Systematic Reviews|May 10, 2017
Partial nephrectomy versus radical nephrectomy for clinical localised renal massesFrank Kunath, Stefanie Schmidt, Laura-Maria Krabbe, et al.
The Cochrane Database of Systematic Reviews|June 14, 2019
Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancerFrank Kunath, Katrin Jensen, Mariona Pinart, et al.
The Cochrane Database of Systematic Reviews|July 1, 2014
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerFrank Kunath, Henrik R Grobe, Gerta Rücker, et al.
BJU International|December 20, 2014
Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic reviewFrank Kunath, Henrik R Grobe, Gerta Rücker, et al.
Annals of Surgical Oncology|October 31, 2012
Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladderBastian Keck, Sven Wach, Frank Kunath, et al.
The Cochrane Database of Systematic Reviews|August 5, 2021
Degarelix for treating advanced hormone-sensitive prostate cancerFriedemann Zengerling, Joachim J Jakob, Stefanie Schmidt, et al.
The Cochrane Database of Systematic Reviews|December 14, 2020
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancerNiranjan J Sathianathen, Makinna C Oestreich, Sarah Jane Brown, et al.
Diagnostics (Basel, Switzerland)|November 14, 2023
Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service PointCarla E Schulmeyer, Matthias W Beckmann, Peter A Fasching, et al.
Pageof 6